Immune System Diseases

905 trials 381 recruiting

Filter these 905 trials by phase, country and sponsor.

Open in Search →

A phase 1 trial to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of VIS171 in participants with … Recruiting

2024-518976-30-00 Systemic lupus erythematosus 3 2025-07-02
A Phase 3, Single-Arm, Multiple-Dose, Pharmacokinetic Comparability Trial Between TAK-881 and HYQVIA in Adults With Chronic Inflammatory Dem… Recruiting

2024-517450-95-00 Chronic inflammatory demyelinating polyradiculoneuropat 5 2025-06-23
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with… Recruiting

2024-513965-38-01 Sjögren's Disease 5 2025-06-16
Long-term safety and efficacy study of riliprubart in participants with CIDP Recruiting

2024-517032-22-00 Immune system diseases. 5 2025-06-10
Belimumab CTD-ILD - Long Term Extension/Follow up to pivotal studies BLISSc-ILD and BEconneCTD-ILD Recruiting

2023-509370-39-00 connective tissue diseases 5 2025-06-03
Long-term Safety and Tolerability of TAK-881 in Subjects with Primary Immunodeficiency Diseases (PIDD) Recruiting

2023-505946-24-00 Primary Immunodeficiency Diseases 5 2025-05-15
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Pso… Recruiting

2024-515706-77-00 Moderate to Severe Plaque Psoriasis 5 2025-05-08
Toward personalized medicine to guide drug withdrawal in children with juvenile idiopathic arthritis in clinical remission: a randomized cli… Recruiting

2024-514732-24-00 Juvenile idiopathic arthritis 6 2025-04-28
A dose ranging study to investigate efficacy and safety of subcutaneous TOUR006 compared with placebo in participants 18 to 80 years of age … Recruiting

2024-514801-69-00 Thyroid Eye Disease 4 2025-04-02
A study to investigate improvement in pruritus of Lichen Simplex Chronicus with dupilumab injections compared with placebo in male and femal… Recruiting

2024-514737-37-00 Neurodermatitis 5 2025-03-06
A study to assess the Efficacy and Safety of Efgartigimod IV in Adult Participants with Primary Immune Thrombocytopenia Recruiting

2024-515451-38-00 Primary Immune thrombocytopenia (ITP) 5 2025-02-27
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis Recruiting

2024-512126-29-00 Generalized Myasthenia Gravis 5 2025-02-25
Multicenter, Open-Label, Randomized Study of Nipocalimab or IVIG in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (F… Recruiting

2023-509434-19-00 Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) 5 2025-02-10
Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 1 (STOP-PN1) Recruiting

2024-511879-16-00 Prurigo Nodularis 5 2024-12-12
Rituximab and obinutuzumab in SLE Recruiting

2024-518965-85-00 Systemic lupus erythematodes 6 2024-11-25
Belimumab in SLE Recruiting

2024-518966-28-00 Systemic lupus erythematodes 6 2024-11-25
Steroid withdrawal in SLE Recruiting

2024-518580-35-00 Systemic Lupus Erythematosus 6 2024-11-20
A randomized, two-period crossover study to demonstrate the comparability of pharmacokinetics of subcutaneous ianalumab between 2mL auto-inj… Recruiting

2023-508996-35-00 Rheumatoid Arthritis 4 2024-11-18
Clinical trial of MDNA11 (investigational drug) administered alone or in combination with pembrolizumab (immune checkpoint inhibitor) in Pat… Recruiting

2023-507536-21-00 Advanced Solid Tumors 7 2024-10-04
A Phase 1b study to investigate safety and tolerability of ARGX-119 in adult participants with DOK7 Congenital Myasthenic Syndrome (CMS) Recruiting

2023-509872-41-00 congenital neuromuscular disorders 9 2024-09-24
A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease Recruiting

2023-508693-29-00 Active, moderate-to-severe TED 3 2024-09-19
A Phase 2 study of DNTH103 in patients with Generalized Myasthenia Gravis Recruiting

2024-512865-15-00 Generalized Myasthenia Gravis 4 2024-09-03
A study of anifrolumab in children and adolescents (5 to < 18 years old) with moderate to severe lupus to find the appropriate anifrolumab d… Recruiting

2022-502289-25-00 Moderate to Severe Active Systemic Lupus Erythematosus 5 2024-08-28
A study of different investigational treatments in people with the interstitial lung disease that accompanies scleroderma (CONQUEST) Recruiting

2023-507129-40-00 interstitial lung disease secondary to systemic scleros 4 2024-08-06